Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 13/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.32 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.32 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.32 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.32 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.32 |
| ▸ | PLK1 | P53350 | 1/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.31 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4367346 | 0.85 | LMNA (0.36) | SMN1; SMN2RIPK1SLC6A2SLC6A4 | |
| SCHEMBL4377976 | 0.84 | RIPK1 (0.36) | TACR1ALDH1A1SMN1; SMN2TDP1CACNA1F | |
| SCHEMBL4379647 | 0.84 | RIPK1 (0.35) | TDP1CACNA1FCACNA1DCACNA1SCACNA1C | |
| SCHEMBL4379146 | 0.83 | TACR1 (0.36) | TACR1ALDH1A1SMN1; SMN2TDP1CACNA1F | |
| SCHEMBL4378296 | 0.82 | TACR1 (0.34) | TACR1ALDH1A1SMN1; SMN2TDP1CACNA1F | |
| SCHEMBL4381009 | 0.81 | TACR1 (0.36) | TACR1ALDH1A1SMN1; SMN2TDP1CACNA1F | |
| SCHEMBL4381006 | 0.80 | TACR1 (0.34) | TACR1ALDH1A1SMN1; SMN2TDP1CACNA1F | |
| SCHEMBL15136972 | 0.80 | BRD4 (0.35) | SMN1; SMN2 | |
| SCHEMBL4369990 | 0.80 | TP53 (0.41) | ALDH1A1SMN1; SMN2RIPK1SLC6A2TAAR1 | |
| SCHEMBL4379046 | 0.78 | TACR1 (0.35) | TACR1TDP1CACNA1FCACNA1DCACNA1S |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2623509-A1 | Method of producing an optically active amine compound by catalytic asymmetric hydrogenation using a ruthenium-diphosphine complex | Kanto Kagaku Kabushiki Kaisha (JP) | 2013-08-07 | — | — | EP | disclosed |
| US-20130197234-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE AMINE COMPOUND | NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (JP) | 2013-08-01 | — | — | US | disclosed |
| US-8212037-B2 | Process for production of optically active quinuclidinols | KANTO KAGAKU KABUSHIKI KAISHA (JP) | 2012-07-03 | — | — | US | disclosed |
| US-20090216019-A1 | Process for Production of Optically Active Quinuclidinols | KANTO KAGAKU KABUSHIKI KAISHA | 2009-08-27 | — | — | US | disclosed |
| EP-1867654-A1 | PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE QUINUCLIDINOL | Nagoya Industrial Science Research Institute (JP) | 2007-12-19 | — | — | EP | disclosed |
| EP-1323724-B1 | Ruthenium complexes and process for preparing alcoholic compounds using these | KANTO KAGAKU (JP) | 2007-03-14 | — | — | EP | disclosed |
| US-6790973-B2 | REDUCTION OF KETONE TO ALCOHOL USING COMPLEX CATALYST | KANTO KAGAKU KABUSHIKI KAISHA (JP) | 2004-09-14 | — | — | US | disclosed |
| US-20030166978-A1 | Novel ruthenium complexes and process for preparing alcoholic compounds using these | KANTO KAGAKU KABUSHIKI KAISHA (JP) | 2003-09-04 | — | — | US | disclosed |
| EP-1323724-A2 | Novel ruthenium complexes and process for preparing alcoholic compounds using these | Kanto Kagaku Kabushiki Kaisha (JP) | 2003-07-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090216019-A1 | Process for Production of Optically Active Quinuclidinols | NQO2, ADH7, MRPL21 | TACR1 3091/4885ALDH1A1 1467/4885SMN1; SMN2 4694/4885 |
| US-20130197234-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE AMINE COMPOUND | HRH3, TDO2, SRM | TACR1 2591/4885ALDH1A1 3607/4885SMN1; SMN2 3025/4885 |
| US-20030166978-A1 | Novel ruthenium complexes and process for preparing alcoholic compounds using these | ADH1C, ADH1A, ADH5 | TACR1 2534/4885ALDH1A1 267/4885SMN1; SMN2 4684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.